Is Too Much Vitamin B12 a Health Hazard?
When observed over an eight-year period, people with the highest plasma concentrations were more likely to die than people with lower levels.
ALL NEWS
6556 RESULTS
Sort By:
- Most Recent
- Most Commented
Herpes Viruses and Alzheimer’s—The Debate Continues
New study finds no uptick in herpes viruses in AD. If herpes plays a role, it says, then probably it acts as an early trigger of pathology.
With a Shot of Adrenaline, Amyloid-β Sparks Tau Cascade
Aβ oligomers latch onto adrenergic receptors, mobilizing a kinase that phosphorylates tau. Blocking adrenergic signaling wards off memory problems in amyloidosis mice.
Paper Alert: Lipid Droplet-Filled Microglia Harm the Brain
These oily microglia resemble the foamy macrophages seen in atherosclerotic plaques. They correlate with aging, inflammation, and neurodegenerative disease.
Human and Mouse Microglia React Differently to Amyloid
Single-nucleus transcriptomics of postmortem AD brain and mouse models of amyloidosis hammers home the species-specific responses of microglia to Aβ pathology.
Vascular Dysfunction Taxes Cognition, but Not Via Amyloid, AD
Three studies found no link between vascular disease and cerebral amyloidosis.
Could New Glutamate Receptor Activators Treat Alzheimer’s?
Positive allosteric modulators improve learning and memory in mouse models of AD and epilepsy.
Does Tau Kill Neurons by Way of Necroptosis?
In Alzheimer’s brain, granulovacuolar bodies in neurons harbor activated necrosomes. They correlate with tau pathology and neuron loss, raising new questions about how neurons die in this disease.
Attack of the Clones? Memory CD8+ T Cells Stalk the AD, PD Brain
The cells are primed to attack. Their targets include Epstein-Barr virus peptides.
Tangle Density Foretells How Fast a Person’s Brain Will Shrink
In early Alzheimer’s disease, the pattern of tau deposition also strongly predicts areas destined for subsequent degeneration.
CTAD Lessons for 2020: More Phase 2 Trials, More Diversity
Besides further broadening the Alzheimer’s therapeutic pipeline, researchers urge a return to Phase 2, using artificial intelligence tools to streamline aspects of trials.
Tau PET Scans Turn Positive When Amyloid Does; Symptoms Follow
Data from different next-generation tracers look similar. It shows spreading plaques kick off tangles by Braak region; memory starts slipping later.
Alzheimer's Disease Research Summit 2019
NIH Summit Sets Agenda for AD-Related Dementias Alzheimer's Disease Research Summit 2019
2019—A Year of Hope for Alzheimer's Research
Happy New Year, readers! Yes, 2019 has passed, but so much happened last year that capturing the essence took longer than usual. Our mega year-end story is now posted for your reading pleasure.
At CTAD, Early Failures and Hints of Success, from Small Trials
A half-dozen lesser-known compounds in trials for Alzheimer’s disease posted results at the CTAD conference.
Current Filters
No filters selected